BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 23151823)

  • 1. Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: model selection, reproducibility, and validation.
    Gaens ME; Backes WH; Rozel S; Lipperts M; Sanders SN; Jaspers K; Cleutjens JP; Sluimer JC; Heeneman S; Daemen MJ; Welten RJ; Daemen JW; Wildberger JE; Kwee RM; Kooi ME
    Radiology; 2013 Jan; 266(1):271-9. PubMed ID: 23151823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions.
    Heye T; Davenport MS; Horvath JJ; Feuerlein S; Breault SR; Bashir MR; Merkle EM; Boll DT
    Radiology; 2013 Mar; 266(3):801-11. PubMed ID: 23220897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study.
    Kim JH; Lee JM; Park JH; Kim SC; Joo I; Han JK; Choi BI
    Radiology; 2013 Jan; 266(1):185-96. PubMed ID: 23192779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracer kinetics analysis of dynamic contrast-enhanced CT and MR data in patients with squamous cell carcinoma of the upper aerodigestive tract: comparison of the results.
    Bisdas S; Baghi M; Wagenblast J; Bisdas T; Thng CH; Mack MG; Koh TS; Ernemann U
    Clin Physiol Funct Imaging; 2009 Sep; 29(5):339-46. PubMed ID: 19473200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
    Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
    Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic MR analysis of the cartilage is influenced by field strength.
    Martí-Bonmatí L; Sanz-Requena R; Alberich-Bayarri A
    Eur J Radiol; 2008 Sep; 67(3):448-52. PubMed ID: 18434058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study.
    Oto A; Fan X; Mustafi D; Jansen SA; Karczmar GS; Rubin DT; Kayhan A
    Acad Radiol; 2009 Oct; 16(10):1223-30. PubMed ID: 19524458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended graphical model for analysis of dynamic contrast-enhanced MRI.
    Chen H; Li F; Zhao X; Yuan C; Rutt B; Kerwin WS
    Magn Reson Med; 2011 Sep; 66(3):868-78. PubMed ID: 21394770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters.
    Franiel T; Lüdemann L; Rudolph B; Rehbein H; Stephan C; Taupitz M; Beyersdorff D
    Radiology; 2009 Jul; 252(1):101-8. PubMed ID: 19561252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of pancreatic cancer by multiple breath-hold dynamic contrast-enhanced magnetic resonance imaging at 3.0T.
    Yao X; Zeng M; Wang H; Sun F; Rao S; Ji Y
    Eur J Radiol; 2012 Aug; 81(8):e917-22. PubMed ID: 22695786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination--pilot study.
    Taylor SA; Punwani S; Rodriguez-Justo M; Bainbridge A; Greenhalgh R; De Vita E; Forbes A; Cohen R; Windsor A; Obichere A; Hansmann A; Rajan J; Novelli M; Halligan S
    Radiology; 2009 May; 251(2):369-79. PubMed ID: 19276323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: application in carcinoma of the cervix.
    Donaldson SB; West CM; Davidson SE; Carrington BM; Hutchison G; Jones AP; Sourbron SP; Buckley DL
    Magn Reson Med; 2010 Mar; 63(3):691-700. PubMed ID: 20187179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
    Port RE; Bernstein LJ; Barboriak DP; Xu L; Roberts TP; van Bruggen N
    Magn Reson Med; 2010 Aug; 64(2):408-17. PubMed ID: 20665785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadofosveset-enhanced magnetic resonance imaging of human carotid atherosclerotic plaques: a proof-of-concept study.
    Lobbes MB; Heeneman S; Passos VL; Welten R; Kwee RM; van der Geest RJ; Wiethoff AJ; Caravan P; Misselwitz B; Daemen MJ; van Engelshoven JM; Leiner T; Kooi ME
    Invest Radiol; 2010 May; 45(5):275-81. PubMed ID: 20351652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing MRI scan time in the computation of pharmacokinetic parameters (K(trans) ) in breast cancer diagnosis.
    Jena A; Mehta SB; Taneja S
    J Magn Reson Imaging; 2013 Sep; 38(3):573-9. PubMed ID: 23349046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal liver metastases: contrast agent diffusion coefficient for quantification of contrast enhancement heterogeneity at MR imaging.
    Jia G; O'Dell C; Heverhagen JT; Yang X; Liang J; Jacko RV; Sammet S; Pellas T; Cole P; Knopp MV
    Radiology; 2008 Sep; 248(3):901-9. PubMed ID: 18710983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of dynamic contrast-enhanced MRI and diffusion-weighted MRI in patients with maxillofacial tumors.
    Kitamoto E; Chikui T; Kawano S; Ohga M; Kobayashi K; Matsuo Y; Yoshiura T; Obara M; Honda H; Yoshiura K
    Acad Radiol; 2015 Feb; 22(2):210-6. PubMed ID: 25442795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.